<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657005</url>
  </required_header>
  <id_info>
    <org_study_id>TK216-01</org_study_id>
    <nct_id>NCT02657005</nct_id>
  </id_info>
  <brief_title>TK216 in Patients With Relapsed or Refractory Ewing Sarcoma</brief_title>
  <official_title>A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncternal Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncternal Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets&#xD;
      family transcription factors driving tumor progression. TK216 is designed to inhibit this&#xD;
      effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a&#xD;
      first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to&#xD;
      establish initial safety and efficacy data in monotherapy and in combination with vincristine&#xD;
      to assess the potential of TK216 for further development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has been expanded to explore single agent TK216 for longer treatment duration.&#xD;
      Approximately 26 patients will be enrolled in this Cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>18 months</time_frame>
    <description>Listing of dose-limiting toxicities by daily dose in mg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>18 months</time_frame>
    <description>Maximum daily dose in mg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biologically effective and recommended Phase 2 dose (RP2D)</measure>
    <time_frame>18 months</time_frame>
    <description>Daily dose in mg/m^2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by Overall Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by Duration of Response (DOR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Disease Control</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay methods to detect EWS-FLI1 (or EWS-ERG and EWS-ets)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve [AUC]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Halflife [T1/2]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: serum miRNA profile</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: tumor tissue RNA assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: tumor tissue protein assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sarcoma, Ewing</condition>
  <arm_group>
    <arm_group_label>TK216 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TK216</intervention_name>
    <description>Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein</description>
    <arm_group_label>TK216 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT)&#xD;
             in subjects with relapsed or refractory disease who have failed standard therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Breitmeyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncternal Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oncternal Information</last_name>
    <phone>858-434-1113</phone>
    <email>clinical@oncternal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubi Arias</last_name>
      <phone>310-794-0345</phone>
      <email>rubiarias@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Noah Federman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew O'hern, BS</last_name>
      <phone>720-777-8557</phone>
      <email>matthew.O'hern@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Macy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Liew, MS</last_name>
      <phone>202-476-6755</phone>
      <email>aliew@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Aerang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Meyers, MD</last_name>
      <phone>833-675-5437</phone>
      <email>meyersp@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Paul A Meyers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Weaver, RN, BSN</last_name>
      <phone>919-681-1883</phone>
      <email>stephanie.weaver@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Hollon, RN, BSN</last_name>
      <phone>919-660-9217</phone>
      <email>lisa.hollon@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Riedel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Anderson, MD, PhD</last_name>
      <phone>216-308-2706</phone>
      <email>andersp@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Peter Anderson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Rodgers</last_name>
      <phone>503-494-4395</phone>
      <email>rodgerbr@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Lara Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer &amp; Hematology Centers, Baylor College</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A Ludwig, MD</last_name>
      <phone>713-792-3626</phone>
    </contact>
    <contact_backup>
      <last_name>Gracy Zacharian</last_name>
      <phone>713-792-2669</phone>
      <email>gzachari@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph A Ludwig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

